U.S. Patent Disclosures
Tuesday, August 16, 2011
Silence Therapeutics plc, of London, received a notice of allowance for a patent directed to the technology involved in AtuPLEX, one of its small interfering RNA delivery systems. It specifically relates to AtuFect, the lipid that serves as the basis for the AtuPLEX delivery system, and covers the system incorporated in lead compound Atu027 and other RNAi candidates.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.